Fazirsiran clinical trials
Also written TAK-999.
How each study uses fazirsiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fazirsiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2023 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 2 |
| 2023 | 3 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses fazirsiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)RecruitingPhase 3TakedaNCT06165341Written as Fazirsiran Injection
- Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin ProteinRecruitingPhase 3TakedaNCT05677971Written as Fazirsiran Injection
- An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver DiseaseActive, not recruitingPhase 3TakedaNCT05899673Written as Fazirsiran Injection
- A Study About Fazirsiran in People With and Without Liver ProblemsCompletedPhase 1TakedaNCT05891158Written as Fazirsiran
- Study of ARO-AAT in Normal Adult VolunteersCompletedPhase 1Arrowhead PharmaceuticalsNCT03362242Written as ARO-AAT Injection
- Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)CompletedPhase 2Arrowhead PharmaceuticalsNCT03945292Written as Fazisiran Injection
- Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)CompletedPhase 2Arrowhead PharmaceuticalsNCT03946449Written as ARO-AAT
Codes
What other systems call fazirsiran · ClinicalTrials.gg INT018185
- UNII (FDA) V20IVC0OGQFAZIRSIRANOne source FDA
- NCI Thesaurus C188640FazirsiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | V20IVC0OGQ | FAZIRSIRAN | One source FDA |
| NCI Thesaurus | C188640 | Fazirsiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.